Glenn P. Muir Buys 25,000 Shares of Neuronetics, Inc. (NASDAQ:STIM) Stock

Neuronetics, Inc. (NASDAQ:STIM) Director Glenn P. Muir bought 25,000 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were purchased at an average price of $0.80 per share, with a total value of $20,000.00. Following the acquisition, the director now directly owns 289,818 shares in the company, valued at approximately $231,854.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Neuronetics Stock Down 1.0 %

NASDAQ STIM opened at $0.78 on Friday. The company has a quick ratio of 2.37, a current ratio of 2.58 and a debt-to-equity ratio of 2.38. Neuronetics, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $5.07. The business has a 50 day moving average price of $1.47 and a two-hundred day moving average price of $2.57. The stock has a market cap of $23.48 million, a PE ratio of -0.81 and a beta of 2.27.

Neuronetics (NASDAQ:STIM) last announced its earnings results on Monday, August 12th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.06). The firm had revenue of $16.45 million during the quarter, compared to analysts’ expectations of $18.76 million. Neuronetics had a negative net margin of 45.06% and a negative return on equity of 109.00%. During the same quarter last year, the company posted ($0.17) earnings per share. As a group, sell-side analysts predict that Neuronetics, Inc. will post -0.87 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. JMP Securities reduced their price target on shares of Neuronetics from $7.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 14th. Canaccord Genuity Group decreased their price target on shares of Neuronetics from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. Finally, William Blair reiterated a “market perform” rating on shares of Neuronetics in a report on Monday, August 12th.

Institutional Trading of Neuronetics

Large investors have recently modified their holdings of the business. First Washington CORP lifted its stake in shares of Neuronetics by 88.8% in the second quarter. First Washington CORP now owns 1,274,540 shares of the company’s stock worth $2,294,000 after acquiring an additional 599,455 shares in the last quarter. Millrace Asset Group Inc. raised its position in shares of Neuronetics by 205.1% in the 4th quarter. Millrace Asset Group Inc. now owns 725,369 shares of the company’s stock valued at $2,104,000 after purchasing an additional 487,591 shares in the last quarter. First Eagle Investment Management LLC boosted its stake in shares of Neuronetics by 33.4% during the 2nd quarter. First Eagle Investment Management LLC now owns 1,039,009 shares of the company’s stock valued at $1,870,000 after buying an additional 260,000 shares during the last quarter. Thompson Siegel & Walmsley LLC acquired a new stake in shares of Neuronetics during the fourth quarter worth approximately $545,000. Finally, Renaissance Technologies LLC increased its stake in shares of Neuronetics by 124.5% in the second quarter. Renaissance Technologies LLC now owns 322,200 shares of the company’s stock worth $580,000 after buying an additional 178,700 shares during the last quarter. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.